Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2001-09-28
2008-09-02
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
active
07419670
ABSTRACT:
Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
REFERENCES:
patent: 5686409 (1997-11-01), McFadden et al.
patent: 5688824 (1997-11-01), Williams
patent: 5917014 (1999-06-01), McFaddenm et al.
patent: 5939525 (1999-08-01), McFadden et al.
patent: 7285530 (2007-10-01), Lucas et al.
patent: 2003/0171263 (2003-09-01), Lucas et al.
patent: 0356945 (1993-11-01), None
patent: 0567816 (1993-11-01), None
patent: 0985412 (2000-03-01), None
patent: 1365798 (2002-04-01), None
patent: 0817646 (2003-01-01), None
patent: 1223971 (2005-06-01), None
patent: H2-108633 (1990-04-01), None
patent: H6-9425 (1994-01-01), None
patent: WO 91/15221 (1991-10-01), None
patent: WO 92/06706 (1992-04-01), None
patent: WO 92/22320 (1992-12-01), None
patent: WO 93/10812 (1993-06-01), None
patent: WO 95/27503 (1995-10-01), None
patent: WO 96/030042 (1996-10-01), None
patent: WO 97/10006 (1997-03-01), None
patent: WO 9962540 (1999-12-01), None
patent: WO 00/45834 (2000-08-01), None
patent: WO 00/53793 (2000-09-01), None
patent: WO 01/30379 (2001-03-01), None
patent: WO 01/30379 (2001-05-01), None
patent: WO 01/38790 (2001-05-01), None
patent: WO 01/039790 (2001-06-01), None
patent: WO 02/026245 (2002-04-01), None
patent: WO 2004/039391 (2004-05-01), None
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Burgess et al ., J Cell Biol. 111:2129-2138, 1990.
Whisstock et al ., Quarterly Review of Biophysics, 2003, 36, pp. 307-340.
Mc Cune et al Curr.Opin Rheumatol, 1993, vol. 3, pp. 282-292.
Strom et al. Therapeutic Immunology, Austen et al. (Ed.) Blackwell Science, Cambridge MA, 1996.
Bernard Hausen, et al., “Viral Serine Proteinase Inhibitor (Serp-1) Effectively Decreases the Incidence of Graft Vasculopathy in Heterotopic Hear Allografts”, Transplantation, vol. 72, pp. 364-368 (2001).
Alexandra Lucas, et al., “Transplant Vasculopathy: Viral Anti-Inflammatory Serpin Regulation of Atherogenesis”, The Journal of Heart and Lung Transplantation, vol. 19, pp. 1029-1038 (2000).
Abstract of Bernard Hausen, et al., “Viral Serine Proteinase Inhibitor (Serp-1) Effectively Decrease the Incidence of Graft Vasculopathy in Heterotopic Hear Allografts”, Transplantation, vol. 72, pp. 364-368 (2001).
Abstract of Alexandra Lucas, et al., “Transplant Vasculopathy: Viral Anti-Inflammatory Serpin Regulation of Atherogenesis”, The Journal of Heart and Lung Transplantation, vol. 19, pp. 1029-1038 (2000).
Aziz et al., “Transplant Arterial Vasculopathy: Evidence for a Dual Pattern of Endothelial Injury and the Source of Smooth Muscle Cells in Lesions of Intimal Hyperplasia,”J. Heart Lung Transplant. 14:S123-S136, 1995.
Abraham et al., “α4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep,”J. Clin. Invest. 93:776-787, 1994.
Abraham et al., “Characterization of a Late Phase Pulmonary Response after Antigen Challenge in Allergic Sheep,”Am. Rev. Respir. Dis. 128:839-844, 1993.
Barsoum, “Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation,”DNA Cell. Biol. 9:293-300, 1990.
Bédard et al., “Prevention of Chronic Renal Allograft Rejection by SERP-1 Protein,”Transplantation81:908-914, 2006.
Ben-Nun et al., “The Rapid Isolation of Clonable Antigen-Specific T Lymphocyte Lines Capable of Mediating Autoimmune Encephalomyelitis,”Eur. J. Immunol. 11:195-199, 1981.
Bowes et al., “Diaspirin Cross-Linked Hemoglobin Improves Neurological Outcome Following Reversible but not Irreversible CNS Ischemia in Rabbits,”Stroke25:2253-2257, 1994.
Burkly et al., “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin,”Diabetes43:529-534, 1994.
Colvin, “CADI,Canti, Cavi,” Transplantation83:677-678, 2007.
Cosimi et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts,”J. Immunol. 144:4604-4612, 1990.
Dai et al., “Serp-1, a Viral Anti-Inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury,”J. Biol. Chem. 278:18563-18572, 2003.
Davis et al., “The Effect of Age on Cerebral Oedema, Cerebral Infarction and Neuroprotective Potential in Experimental Occlusive Stroke,”Acta Neurochir. Suppl. 60:282-284, 1994.
Davison and Moss, “New Vaccinia Virus Recombination Plasmids Incorporating a Synthetic Late Promoter for High Level Expression of Foreign Proteins,”Nucl. Acids Res. 18:4285-4286, 1990.
Doerschuk et al., “CD18-Dependent and -Independent Mechanisms of Neutrophil Emigration in the Pulmonary and Systemic Microcirculation of Rabbits,”J. Immunol. 144:2327-2333, 1990.
Fava et al., “Transforming Growth Factor β1 (TGF-β1) Induced Neutrophil Recruitment to Synovial Tissues: Implications for TGF- β-Driven Synovial Inflammation and Hyperplasia,”J. Exp. Med. 173:1121-1132, 1991.
Friedrichs et al., “Effects of Heparin and N-Acetyl Heparin on Ischemia/Reperfusion-Induced Alterations in Myocardial Function in the Rabbit Isolated Heart,”Circulation Res. 75:701-710, 1994.
Fritz, “Proteinase Inhibitors in Severe Inflammatory Processes (Septic Shock and Experimental Endotoxaemia): Biochemical, Pathophysiological and Therapeutic Aspects,” InProtein Degradation in Health and Disease, Ciba Foundation Symposium75:351-379, 1980.
Gilhar and Etzioni, “The Nude Mouse Model for the Study of Human Skin Disorders,”Dermatology189:5-8, 1994.
Gooding et al., “Virus Proteins that Counteract Host Immune Defenses”Cell71:5-7, 1992.
Gown et al., “Human Atherosclerosis- Immunocytochemical Analysis of the Cellular Composition of Human Atherosclerotic Lesions,”Am. J. Physiol. 125:191-207, 1986.
Haber, “Can a Viral Serine Proteinase Inhibitor Prevent Postangioplasty Restenosis?”Circulation94:2694-2695, 1996.
Hagerty and Allen, “Tolerance to Self and the Processing and Presentation of Self Antigens,”Intern. Rev. Immunol. 10:313-319, 1993.
Hammer et al., “Spontaneous Inflammatory Disease in Transgenic Rates Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders,”Cell63:1099-1112, 1990.
Harlan et al., “In Vivo Models of Leukocyte Adherence to Endothelium,” inAdhesion: Its Role in Inflammatory Disease, Harlan et al. (eds.), W.H. Freeman and Co., New York, 1992, p. 117-150.
Häyry et al., “Chronic Allograft Rejection,”Transplantation Proc. 28;2337-2338, 1996.
Herzum et al., “Coxsackievirus B3 Infection Leads to Cell Death of Cardiac Myocytes,”J. Mol. Cell. Cardiol. 26:907-913, 1994.
Hickey et al., “T-Lymphocyte Entry Into the Central Nervous System,”J. Neurosci. Res. 28:254-260, 1991.
Hill et al., “Soluble Complement Receptor Type 1 Ameliorates the Local and Remote Organ Injury After Intestinal Ischemia-Reperfusion in the Rat,”J. Immunol. 149:1723-1728, 1992.
Howie and Helyer, “The Immunology and Pathology of NZB Mice,”Adv. Immunol. 198:215-266, 1968.
Huber and Pfaeffle, “Differential Th1and Th2Cell Responses in Male and Female BALB/c Mice Infected with Coxsackievirus Group B Type 3,”J. Virology68:5126-5132, 1994.
Jiang and Kanost, “Characterization and Functional Analysis of 12 Naturally Occurring Reactive Site Variants of Serpin-1 fromManduca Sexta,” J. Biol. Chem. 272:1082-1087, 1997.
Jiang et al., “Induction of Indefinite Cardiac
Lucas Alexandra
McFadden Grant D.
Zhong Robert Z.
Belyavskyi Michail A
Bieker-Brady Kristina
Clark & Elbing LLP
Viron Therapeutics Inc.
LandOfFree
Method of treating arthritis with SERP-1 and an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating arthritis with SERP-1 and an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating arthritis with SERP-1 and an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990881